Paul H. Klingenstein, Director at Clovis Oncology, Inc. (CLVS), bought 402,453 shares at $13.00 ($5.2M) on 2011-11-21, disclosed to the SEC on 2012-03-22.
Open-market purchase of $5.2M CLVS by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 3,162 | $0 | 0.0% |
| 2 | $13.00 | 7,813 | $102K | 2.0% |
| 3 | $13.00 | 391,478 | $5.1M | 98.0% |
| Total | $12.90 avg | 402,453 | $5.2M | 100% |
| Filing → |
| ANAC | BUY | 2010-12-01 | $1.5M | — | Filing → |
| ETRM | BUY | 2009-02-25 | $1.4M | — | Filing → |
| ETRM | BUY | 2008-06-03 | $207K | — | Filing → |